Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Regenxbio Rs LLC currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, showing that each case is being handled independently by different personnel. This distribution suggests that the company's current patent efforts cover diverse technical sub-fields within the Biotechnology & Pharmaceuticals sector. The involvement of 2 distinct art units implies that the applications are being reviewed by different specialized groups. The lack of concentration in a single art unit may require the legal team to adapt to different procedural styles.
NGHI V NGUYEN is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending action. The alignment of 2 distinct examiners with 2 distinct art units suggests that the active prosecution spans different specialized groups within the technology area. With 2 pending office actions in total, the company's legal team must coordinate with 2 distinct examiners. This structure ensures that no single examiner's perspective dominates the company's current patent outcomes. Practitioners should focus on the 1 busiest examiner pending action while maintaining a flexible approach for the other distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +59.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18480172 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | NGUYEN, NGHI V | — |
| 17260732 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | VYAS, KEYUR ANILKUMAR | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18480172 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | NGUYEN, NGHI V | 1653 | §103 | Non-Final OA | — | Pending | Oct 03, 2023 |
| 17260732 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | VYAS, KEYUR ANILKUMAR | 1637 | §103§112DP | Non-Final OA | — | Pending | Jan 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenxbio Rs LLC has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Nghi V Nguyen has the most, with 1 of Regenxbio Rs LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.